Repligen to Acquire BioLife Solutions for $1.5B in Cash and Stock
BLFS sits 63% above its 52-week low of $17.86.
Summary
Repligen is acquiring BioLife Solutions in a $1.5 billion enterprise value deal, paying $31 per share — a mix of $11.25 cash and 0.1442 Repligen shares. This follows takeover speculation reported in late June, but now we have a definitive agreement with concrete terms. The deal expands Repligen's cell therapy capabilities with BioLife's market-leading biopreservation media. Repligen expects at least $20 million in synergies in year one and $30 million in year two, with the deal accretive to adjusted EPS by $0.05 in year one and $0.25 in year two. BioLife also disclosed preliminary Q2 revenue of $28.5 million, up 21% year-over-year, showing strong standalone momentum. The acquisition price represents a premium to BioLife's recent trading levels and validates the strategic value of its biopreservation platform. For BioLife shareholders, the stock component provides ongoing exposure to the combined entity's cell therapy growth. The deal is expected to close subject to customary conditions and regulatory approvals.
At the time of this announcement, BLFS was trading at $29.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $17.86 to $30.88. This news item was assessed with positive market sentiment and an importance score of 10 out of 10. Source: Reuters.